Drugs / ABI-110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06550011 | Aug 2024 → Jan 2027 expected | wet macular degeneration | Avirmax Biopharma Inc | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABI-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06550011 ↗ |
| Known as | AAV2.N54-VEGF-Trap | “A Phase 1/2a, Open-Label, Multiple-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110...” NCT06550011 ↗ |
| Route | Intravitreal | “Intravitreal (IVT) injection” NCT06550011 ↗ |